Fig. 1

YTHDC2 promotes ZNRD1-AS1 stability in lung malignant cells. A YTHDC2 RIP sequencing identifies lncRNAs capable of binding to YTHDC2. B Correlation analysis between the expression of YTHDC2 and ZNRD1-AS1 in LUAD and LUSC datasets. C RIP sequencing and correlation analysis identified ZNRD1-AS1 as the putative target of YTHDC2. D RIP-PCR validation of YTHDC2 binding to ZNRD1-AS1. E qPCR was performed to detect the expression levels of ZNRD1-AS1 following the overexpression or knockdown of YTHDC2 in H1299 and S30 cells. *** P < 0.001 vs. siNC, ## P < 0.01 and ### P < 0.001 vs. Blank. F ZNRD1-AS1 expression levels in tumor formed subcutaneously by H1299 cells overexpressing YTHDC2 in nude mice. G Expression levels of YTHDC2 in pan-cancer based on TCGA and GTEx databases. * P < 0.05, ** P < 0.01 and *** P < 0.001 normal vs. tumor. H Relative expression of ZNRD1-AS1 in cigarette smoke-exposed BEAS-2B cells and H1299 lung cancer cells. S10, S20 and S30 represent BEAS-2B cells exposed to CS for 10, 20 and 30 passages, respectively. ** P < 0.01 and *** P < 0.01 vs. BEAS-2B group. RNA stability assay to explore the effect of overexpression or knockdown of YTHDC2 on ZNRD1-AS1 stability in (I) S30 and (J) H1299 cells. RIP: RNA immunoprecipitation. LUAD: Lung adenocarcinoma. LUSC: Lung squamous cell carcinoma. qPCR: quantitative PCR. siNC: negative control for siRNA transfection. TCGA: The Cancer Genome Atlas. GTEx: The Genotype-Tissue Expression. CS: cigarette smoke